Financhill
Buy
68

AKBA Quote, Financials, Valuation and Earnings

Last price:
$3.97
Seasonality move :
-6.24%
Day range:
$3.91 - $4.08
52-week range:
$1.07 - $4.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.68x
P/B ratio:
41.99x
Volume:
2.7M
Avg. volume:
5.7M
1-year change:
209.45%
Market cap:
$1B
Revenue:
$160.2M
EPS (TTM):
-$0.21

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AKBA
Akebia Therapeutics
$47.6M -$0.03 8.03% -- $7.40
ALNY
Alnylam Pharmaceuticals
$641.1M -$0.01 -3.52% -58.59% $329.54
ARDX
Ardelyx
$82.5M -$0.14 12.93% -95.54% $10.73
BPMC
Blueprint Medicines
$171.3M -$0.53 24.15% -36.72% $126.87
HRTX
Heron Therapeutics
$38.1M -$0.01 5.69% -83.33% $6.25
TGTX
TG Therapeutics
$145.3M $0.28 101.13% 653.48% $40.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AKBA
Akebia Therapeutics
$3.93 $7.40 $1B -- $0.00 0% 4.68x
ALNY
Alnylam Pharmaceuticals
$314.94 $329.54 $41.1B -- $0.00 0% 17.24x
ARDX
Ardelyx
$4.49 $10.73 $1.1B -- $0.00 0% 2.94x
BPMC
Blueprint Medicines
$129.30 $126.87 $8.4B -- $0.00 0% 14.74x
HRTX
Heron Therapeutics
$2.18 $6.25 $332.6M -- $0.00 0% 2.25x
TGTX
TG Therapeutics
$37.09 $40.50 $5.9B 154.52x $0.00 0% 15.43x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AKBA
Akebia Therapeutics
65.42% 2.042 9.26% 1.92x
ALNY
Alnylam Pharmaceuticals
89.88% 0.837 2.91% 2.84x
ARDX
Ardelyx
50.95% -0.143 12.88% 3.43x
BPMC
Blueprint Medicines
53.13% 2.692 6.79% 2.62x
HRTX
Heron Therapeutics
119.42% -2.666 52.18% 1.46x
TGTX
TG Therapeutics
-- -0.654 -- 2.01x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AKBA
Akebia Therapeutics
$49.7M $13.5M -406.64% -- 24.21% -$13.6M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
ARDX
Ardelyx
$61.8M -$36.3M -19.51% -34.68% -45.91% -$38.8M
BPMC
Blueprint Medicines
$146.6M -$41.1M -23.09% -49.13% 12.78% -$56.3M
HRTX
Heron Therapeutics
$30.4M $3.2M -5.57% -- 8.11% -$9M
TGTX
TG Therapeutics
$105.3M $8.6M 11.64% 19.78% 10.12% -$28.7M

Akebia Therapeutics vs. Competitors

  • Which has Higher Returns AKBA or ALNY?

    Alnylam Pharmaceuticals has a net margin of 10.66% compared to Akebia Therapeutics's net margin of -9.67%. Akebia Therapeutics's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    86.7% $0.03 $71.1M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About AKBA or ALNY?

    Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 88.3%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $329.54 which suggests that it could grow by 4.64%. Given that Akebia Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Akebia Therapeutics is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    3 0 0
    ALNY
    Alnylam Pharmaceuticals
    13 7 1
  • Is AKBA or ALNY More Risky?

    Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

  • Which is a Better Dividend Stock AKBA or ALNY?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or ALNY?

    Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Akebia Therapeutics's net income of $6.1M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.68x versus 17.24x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    4.68x -- $57.3M $6.1M
    ALNY
    Alnylam Pharmaceuticals
    17.24x -- $594.2M -$57.5M
  • Which has Higher Returns AKBA or ARDX?

    Ardelyx has a net margin of 10.66% compared to Akebia Therapeutics's net margin of -55.52%. Akebia Therapeutics's return on equity of -- beat Ardelyx's return on equity of -34.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    86.7% $0.03 $71.1M
    ARDX
    Ardelyx
    83.4% -$0.17 $297M
  • What do Analysts Say About AKBA or ARDX?

    Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 88.3%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 138.92%. Given that Ardelyx has higher upside potential than Akebia Therapeutics, analysts believe Ardelyx is more attractive than Akebia Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    3 0 0
    ARDX
    Ardelyx
    8 1 0
  • Is AKBA or ARDX More Risky?

    Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

  • Which is a Better Dividend Stock AKBA or ARDX?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or ARDX?

    Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than Ardelyx quarterly revenues of $74.1M. Akebia Therapeutics's net income of $6.1M is higher than Ardelyx's net income of -$41.1M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.68x versus 2.94x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    4.68x -- $57.3M $6.1M
    ARDX
    Ardelyx
    2.94x -- $74.1M -$41.1M
  • Which has Higher Returns AKBA or BPMC?

    Blueprint Medicines has a net margin of 10.66% compared to Akebia Therapeutics's net margin of 0.33%. Akebia Therapeutics's return on equity of -- beat Blueprint Medicines's return on equity of -49.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    86.7% $0.03 $71.1M
    BPMC
    Blueprint Medicines
    98.13% $0.01 $729.9M
  • What do Analysts Say About AKBA or BPMC?

    Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 88.3%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.88%. Given that Akebia Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Akebia Therapeutics is more attractive than Blueprint Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    3 0 0
    BPMC
    Blueprint Medicines
    2 15 1
  • Is AKBA or BPMC More Risky?

    Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

  • Which is a Better Dividend Stock AKBA or BPMC?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or BPMC?

    Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Akebia Therapeutics's net income of $6.1M is higher than Blueprint Medicines's net income of $496K. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.68x versus 14.74x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    4.68x -- $57.3M $6.1M
    BPMC
    Blueprint Medicines
    14.74x -- $149.4M $496K
  • Which has Higher Returns AKBA or HRTX?

    Heron Therapeutics has a net margin of 10.66% compared to Akebia Therapeutics's net margin of 6.77%. Akebia Therapeutics's return on equity of -- beat Heron Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    86.7% $0.03 $71.1M
    HRTX
    Heron Therapeutics
    78.26% $0.02 $146.5M
  • What do Analysts Say About AKBA or HRTX?

    Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 88.3%. On the other hand Heron Therapeutics has an analysts' consensus of $6.25 which suggests that it could grow by 186.7%. Given that Heron Therapeutics has higher upside potential than Akebia Therapeutics, analysts believe Heron Therapeutics is more attractive than Akebia Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    3 0 0
    HRTX
    Heron Therapeutics
    2 0 0
  • Is AKBA or HRTX More Risky?

    Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison Heron Therapeutics has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.163%.

  • Which is a Better Dividend Stock AKBA or HRTX?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Heron Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. Heron Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or HRTX?

    Akebia Therapeutics quarterly revenues are $57.3M, which are larger than Heron Therapeutics quarterly revenues of $38.9M. Akebia Therapeutics's net income of $6.1M is higher than Heron Therapeutics's net income of $2.6M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while Heron Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.68x versus 2.25x for Heron Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    4.68x -- $57.3M $6.1M
    HRTX
    Heron Therapeutics
    2.25x -- $38.9M $2.6M
  • Which has Higher Returns AKBA or TGTX?

    TG Therapeutics has a net margin of 10.66% compared to Akebia Therapeutics's net margin of 4.19%. Akebia Therapeutics's return on equity of -- beat TG Therapeutics's return on equity of 19.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKBA
    Akebia Therapeutics
    86.7% $0.03 $71.1M
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
  • What do Analysts Say About AKBA or TGTX?

    Akebia Therapeutics has a consensus price target of $7.40, signalling upside risk potential of 88.3%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 9.21%. Given that Akebia Therapeutics has higher upside potential than TG Therapeutics, analysts believe Akebia Therapeutics is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKBA
    Akebia Therapeutics
    3 0 0
    TGTX
    TG Therapeutics
    5 1 0
  • Is AKBA or TGTX More Risky?

    Akebia Therapeutics has a beta of 0.882, which suggesting that the stock is 11.791% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

  • Which is a Better Dividend Stock AKBA or TGTX?

    Akebia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akebia Therapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKBA or TGTX?

    Akebia Therapeutics quarterly revenues are $57.3M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Akebia Therapeutics's net income of $6.1M is higher than TG Therapeutics's net income of $5.1M. Notably, Akebia Therapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 154.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akebia Therapeutics is 4.68x versus 15.43x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKBA
    Akebia Therapeutics
    4.68x -- $57.3M $6.1M
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 14

MiNK Therapeutics [INKT] is down 36.11% over the past day.

Buy
51
NEGG alert for Jul 14

Newegg Commerce [NEGG] is down 22.12% over the past day.

Buy
68
ATRO alert for Jul 14

Astronics [ATRO] is down 2.27% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock